HHLR ADVISORS, LTD.HHLR ADVISORS, LTD.

Institutional investor · Portfolio as of Q2 2024

SEC EDGAR SourceSEC Filings

Top Holdings78 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
PDDPDD
ADR

PDD HOLDINGS INC

8.9M$1.2B29.2%$97.08+36.95%
9 qtrssince 2022-Q2
Decreased
0
ONCONC
ADR

BEIGENE LTD-ADR

5.2M$738.6M18.2%$134.02+6.45%
23 qtrssince 2018-Q4
Unchanged
0
BABABABA
ADR

ALIBABA GROUP HOLDING-SP ADR

5.4M$387.3M9.6%$71.55-1.04%
9 qtrssince 2022-Q2
Increased
98
BEKEBEKE
ADR

KE HOLDINGS INC-ADR

23.2M$327.9M8.1%$21.97-36.92%
16 qtrssince 2020-Q3
Decreased
0
LEGNLEGN
ADR

Legend Biotech Corp. Sponsored ADR

6.6M$293.9M7.3%$50.33-12.00%
17 qtrssince 2020-Q2
Increased
67
VIPSVIPS
ADR

VIPSHOP HLDGS LTD

14.8M$192.8M4.8%$12.540.00%
14 qtrssince 2021-Q1
Increased
90
NTESNTES
ADR

NETEASE INC-ADR

1.4M$132.5M3.3%$89.54+2.95%
7 qtrssince 2022-Q4
Increased
89

ARRIVENT BIOPHARMA INC

4.5M$83.2M2.1%$17.95+3.37%
2 qtrssince 2024-Q1
Increased
58
TCOMTCOM
ADR

TRIP.COM GROUP LTD-ADR

1.4M$65.1M1.6%$46.770.00%
1 qtr
New
67

KINIKSA PHARMACEUTICALS INTL

3.1M$58.7M1.4%$18.670.00%
1 qtr
New
67
FUTUFUTU
ADR

FUTU HLDGS LTD

716,089$47M1.2%$64.090.00%
1 qtr
New
67
ENFNENFNDelisted

ENFUSION INC

5M$42.4M1.0%
11 qtrssince 2021-Q4
Unchanged
0

CYTEK BIOSCIENCES INC

6.7M$37.1M0.9%$20.96-73.38%
12 qtrssince 2021-Q3
Unchanged
0

BRIDGEBIO PHARMA INC

1.4M$35.2M0.9%$28.21-10.20%
21 qtrssince 2019-Q2
Increased
41

DANAHER CORP

108,700$27.2M0.7%$225.13+10.05%
5 qtrssince 2023-Q2
Decreased
0

DOORDASH INC - A

247,912$27M0.7%$116.24+86.70%
15 qtrssince 2020-Q4
Decreased
0

SALESFORCE.COM INC

96,358$24.8M0.6%$206.97-5.20%
18 qtrssince 2020-Q1
Decreased
0

META PLATFORMS INC-CLASS A

44,476$22.4M0.6%$499.18+0.51%
2 qtrssince 2024-Q1
Increased
65
AZNAZN
ADR

ASTRAZENECA PLC

271,749$21.2M0.5%$151.98+2.94%
1 qtr
New
56
HTHTHTHT
ADR

H WORLD GROUP LTD

568,613$18.9M0.5%$42.46-27.23%
17 qtrssince 2020-Q2
Decreased
0
$4.1B
AUM
78
Positions
Q2 2024
Filing
Rating · 3.5
Quarterly Portfolio Change
+19%Q1'23$5.6B-17%Q2'23$4.7B-5%Q3'23$4.5B+11%Q4'23$5B-7%Q1'24$4.6B-12%Q2'24$4.1B
Activity profile
$ moved · Q2'24
New11%Increased32%Decreased42%Exited15%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.3 years
<1Q24%1-4Q14%1-2Y6%2Y+55%

HHLR ADVISORS, LTD. manages $4.1B across 78 positions as of Q2 2024. Top holdings: PDD (29.2%), ONC (18.2%), BABA (9.6%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3.5/5.0.

Q2 2024 Summary

Active quarter - 25 new positions, 10 exits, 17 increased. Top move: BABA (INCREASED, conviction 98). Portfolio: $4.1B across 78 positions.

Top holdings by portfolio weight

Total AUM$4B
PDD29.16%
ONC18.22%
BABA9.55%
BEKE8.09%
LEGN7.25%
VIPS4.76%
NTES3.27%
AVBP2.05%
TCOM1.61%
KNSA1.45%
Other1.16%

Portfolio allocation by GICS sector

Sectors10
Consumer Cyclical47.51%
Healthcare33.80%
Real Estate8.09%
Communication Services4.98%
Technology2.39%
Financial Services1.34%
Unknown1.27%
Consumer Defensive0.46%
Industrials0.14%
Energy0.04%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Consumer Cyclical, Healthcare
Compare DNA across all funds
7-dimension quality assessment
Strong(3.5 / 5.0)
Track RecordNo data
Conviction42
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used